Estradiol transdermal one 90 μL spray — Competitive Intelligence Brief

Estradiol transdermal one 90 μL spray (Estradiol transdermal one 90 μL spray) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT) / Estrogen. Area: Endocrinology / Women's Health.

phase 3 Hormone replacement therapy (HRT) / Estrogen Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ) Endocrinology / Women's Health Small molecule

Target snapshot

Estradiol transdermal one 90 μL spray (Estradiol transdermal one 90 μL spray) — Lumara Health, Inc.. Estradiol transdermal spray delivers the hormone estradiol through the skin to replace or supplement endogenous estrogen levels.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Estradiol transdermal one 90 μL spray TARGET	Estradiol transdermal one 90 μL spray	Lumara Health, Inc.	phase 3	Hormone replacement therapy (HRT) / Estrogen	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
Transdermal strogen	Transdermal strogen	Parc de Salut Mar	marketed	Hormone replacement therapy (HRT) / Estrogen replacement	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT) / Estrogen class)

1. Lumara Health, Inc. · 1 drug in this class